FBXO7 and colorectal carcinoma: This study employed bioinformatics analyses, small interfering RNA (siRNA) screening, small molecule inhibition, and quantitative imaging (QuantIM) microscopy to identify synthetic lethal interactors of FBXO7. Shallow deletions of FBXO7 in CRC patient samples was found to associate with decreased gene expression and adverse clinical outcomes.